GET THE APP

Novel Therapeutics in Lung Cancer | 92573

Rapports de cas d'oncologie et de cancer

ISSN - 2471-8556

Abstrait

Novel Therapeutics in Lung Cancer

Rana Hadir

In contrast to the widely held belief that a higher BMI reduces the survival and/or incidence of many malignant tumours (such as colonic, pancreatic, and postmenopausal breast cancers), obesity (defined as BMI>30 kg/m2) would be protective for the survival and/or occurrence of a few malignancies, including large B-cell lymphomas, renal, and Non-Small Cell Lung Cancer (NSCLC). This "obesity paradox" has been proposed by epidemiological studies and a recent meta-analysis focusing on NSCLC.

Clause de non-responsabilité : Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été révisé ou vérifié.